Pancragen 20 mg is a peptide-based bioregulator supplied by Peptide Sciences USA and designed exclusively for laboratory and research applications. This cytogenetic peptide is derived from pancreatic tissue and is studied for its ability to normalize pancreas-specific gene expression, promote tissue repair, and support endocrine function—especially in the context of aging or metabolic dysfunction.
Mechanism of Action
Pancragen acts at the epigenetic level by targeting specific gene regions in pancreatic cells. In research models, it supports the normalization of mRNA synthesis and protein production in pancreatic islet cells, which are responsible for insulin and glucagon regulation. This modulation may contribute to improved glucose metabolism and endocrine homeostasis.
Studies have shown that Pancragen may influence both exocrine and endocrine functions of the pancreas, offering potential for investigating cellular rejuvenation, reduced inflammation, and restoration of enzymatic activity. It has been explored as part of a wider class of tissue-specific peptide bioregulators developed for age-associated organ decline and chronic conditions.
Key Features & Benefits
- Pancreatic Gene Regulation: Supports research on normalization of insulin-producing beta-cell function and hormonal secretion.
- Cytogenetic Modulation: Acts directly on chromatin to restore cellular transcription balance in pancreatic tissue.
- Anti-Aging Applications: Studied for effects on endocrine rejuvenation and age-related metabolic decline.
- Research on Glucose Metabolism: Potential utility in metabolic, diabetic, or glycemic stability models.
- High-Purity Research Grade: Provided by Peptide Sciences USA under stringent peptide manufacturing conditions.
Legal Disclaimer
Disclaimer: Pancragen is intended for research use only. It is not approved for human or veterinary use. All handling should occur in laboratory environments by trained professionals following institutional guidelines.
Frequently Asked Questions
Pancragen is a cytogenetic peptide studied for its potential to regulate pancreatic gene expression and support endocrine system balance.
It is used to explore restoration of pancreatic tissue, insulin regulation, and glucose metabolism in models of aging and metabolic disorders.
No, Pancragen does not mimic insulin. It is studied for upstream regulation of pancreas-specific transcription and peptide signaling associated with insulin production.
No, Pancragen is not approved by the FDA. It is sold exclusively for research purposes and is not intended for therapeutic or clinical use.
Store the lyophilized powder at -20°C. Once reconstituted, it should be refrigerated at 2–8°C and used within the recommended stability window.
